文章来自Maiwald博客
EPO Board of Appeal 3.3.04 is setting the right standard for acknowledging novelty of non-medical use claims (T 1913/21)
G 2/88 provides legal assessment for novelty of a non-medical use claim. G 2/88 allows acknowledging novelty of a non-medical use claim of an old compound for a particular pur...
Continue reading
EPO revokes Roche’s Patent on combination therapy of bevacizumab and paclitaxel for platinum-resistant ovarian cancer that was supported by results of Phase III AURELIA clinical trial
European Patent EP 2 825 558 concerns a combination therapy of bevacizumab and paclitaxel for platinum-resistant ovarian cancer. The claim was supported by Phase III AURELIA c...
Continue reading
UPDATE: New proceedings before the Enlarged Board of Appeal: “G2/24 – Skin cleanser”
On the issue of the potential continuation of EPO appeal proceedings by an intervener the questions for referral on which we already reported
Continue reading
New referral to the Enlarged Board of Appeal – continuation of the appeal by intervener – T1286/23
In the opposition appeal proceedings “T1286/23”, which we had already reported on “
Continue reading
Equivalent infringement in different European jurisdictions
As part of our regular internal legal seminars, Dr. Wilhelm Eger held a talk on current developments in infringement under the doctrine of equivalency in various European lega...
Continue reading
Implementation of the Pharmaceutical Strategy for Europe and the Intellectual Property Action Plan – Part 3
In addition to the pharmaceutical strategy for Europe[1], the European Commission adopted a new action plan for intellectual prop...
Continue reading
